Cargando…
A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma
BACKGROUND: Although dendritic cell (DC) vaccines are considered to be promising treatments for advanced cancer, their production and administration is costly and labor-intensive. We developed a novel immunotherapeutic agent that links a single-chain antibody variable fragment (scFv) targeting mesot...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943805/ https://www.ncbi.nlm.nih.gov/pubmed/24565018 http://dx.doi.org/10.1186/1756-8722-7-15 |
_version_ | 1782306305276379136 |
---|---|
author | Yuan, Jianping Kashiwagi, Satoshi Reeves, Patrick Nezivar, Jean Yang, Yuan Arrifin, Nadiah Hashim Nguyen, Mai Jean-Mary, Gilberte Tong, Xiaoyun Uppal, Paramjit Korochkina, Svetlana Forbes, Ben Chen, Tao Righi, Elda Bronson, Roderick Chen, Huabiao Orsulic, Sandra Brauns, Timothy Leblanc, Pierre Scholler, Nathalie Dranoff, Glenn Gelfand, Jeffrey Poznansky, Mark C |
author_facet | Yuan, Jianping Kashiwagi, Satoshi Reeves, Patrick Nezivar, Jean Yang, Yuan Arrifin, Nadiah Hashim Nguyen, Mai Jean-Mary, Gilberte Tong, Xiaoyun Uppal, Paramjit Korochkina, Svetlana Forbes, Ben Chen, Tao Righi, Elda Bronson, Roderick Chen, Huabiao Orsulic, Sandra Brauns, Timothy Leblanc, Pierre Scholler, Nathalie Dranoff, Glenn Gelfand, Jeffrey Poznansky, Mark C |
author_sort | Yuan, Jianping |
collection | PubMed |
description | BACKGROUND: Although dendritic cell (DC) vaccines are considered to be promising treatments for advanced cancer, their production and administration is costly and labor-intensive. We developed a novel immunotherapeutic agent that links a single-chain antibody variable fragment (scFv) targeting mesothelin (MSLN), which is overexpressed on ovarian cancer and mesothelioma cells, to Mycobacterium tuberculosis (MTB) heat shock protein 70 (Hsp70), which is a potent immune activator that stimulates monocytes and DCs, enhances DC aggregation and maturation and improves cross-priming of T cells mediated by DCs. METHODS: Binding of this fusion protein with MSLN on the surface of tumor cells was measured by flow cytometry and fluorescence microscopy. The therapeutic efficacy of this fusion protein was evaluated in syngeneic and orthotopic mouse models of papillary ovarian cancer and malignant mesothelioma. Mice received 4 intraperitoneal (i.p.) treatments with experimental or control proteins post i.p. injection of tumor cells. Ascites-free and overall survival time was measured. For the investigation of anti-tumor T-cell responses, a time-matched study was performed. Splenocytes were stimulated with peptides, and IFNγ- or Granzyme B- generating CD3(+)CD8(+) T cells were detected by flow cytometry. To examine the role of CD8(+) T cells in the antitumor effect, we performed in vivo CD8(+) cell depletion. We further determined if the fusion protein increases DC maturation and improves antigen presentation as well as cross-presentation by DCs. RESULTS: We demonstrated in vitro that the scFvMTBHsp70 fusion protein bound to the tumor cells used in this study through the interaction of scFv with MSLN on the surface of these cells, and induced maturation of bone marrow-derived DCs. Use of this bifunctional fusion protein in both mouse models significantly enhanced survival and slowed tumor growth while augmenting tumor-specific CD8(+) T-cell dependent immune responses. We also demonstrated in vitro and in vivo that the fusion protein enhanced antigen presentation and cross-presentation by targeting tumor antigens towards DCs. CONCLUSIONS: This new cancer immunotherapy has the potential to be cost-effective and broadly applicable to tumors that overexpress mesothelin. |
format | Online Article Text |
id | pubmed-3943805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39438052014-03-06 A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma Yuan, Jianping Kashiwagi, Satoshi Reeves, Patrick Nezivar, Jean Yang, Yuan Arrifin, Nadiah Hashim Nguyen, Mai Jean-Mary, Gilberte Tong, Xiaoyun Uppal, Paramjit Korochkina, Svetlana Forbes, Ben Chen, Tao Righi, Elda Bronson, Roderick Chen, Huabiao Orsulic, Sandra Brauns, Timothy Leblanc, Pierre Scholler, Nathalie Dranoff, Glenn Gelfand, Jeffrey Poznansky, Mark C J Hematol Oncol Research BACKGROUND: Although dendritic cell (DC) vaccines are considered to be promising treatments for advanced cancer, their production and administration is costly and labor-intensive. We developed a novel immunotherapeutic agent that links a single-chain antibody variable fragment (scFv) targeting mesothelin (MSLN), which is overexpressed on ovarian cancer and mesothelioma cells, to Mycobacterium tuberculosis (MTB) heat shock protein 70 (Hsp70), which is a potent immune activator that stimulates monocytes and DCs, enhances DC aggregation and maturation and improves cross-priming of T cells mediated by DCs. METHODS: Binding of this fusion protein with MSLN on the surface of tumor cells was measured by flow cytometry and fluorescence microscopy. The therapeutic efficacy of this fusion protein was evaluated in syngeneic and orthotopic mouse models of papillary ovarian cancer and malignant mesothelioma. Mice received 4 intraperitoneal (i.p.) treatments with experimental or control proteins post i.p. injection of tumor cells. Ascites-free and overall survival time was measured. For the investigation of anti-tumor T-cell responses, a time-matched study was performed. Splenocytes were stimulated with peptides, and IFNγ- or Granzyme B- generating CD3(+)CD8(+) T cells were detected by flow cytometry. To examine the role of CD8(+) T cells in the antitumor effect, we performed in vivo CD8(+) cell depletion. We further determined if the fusion protein increases DC maturation and improves antigen presentation as well as cross-presentation by DCs. RESULTS: We demonstrated in vitro that the scFvMTBHsp70 fusion protein bound to the tumor cells used in this study through the interaction of scFv with MSLN on the surface of these cells, and induced maturation of bone marrow-derived DCs. Use of this bifunctional fusion protein in both mouse models significantly enhanced survival and slowed tumor growth while augmenting tumor-specific CD8(+) T-cell dependent immune responses. We also demonstrated in vitro and in vivo that the fusion protein enhanced antigen presentation and cross-presentation by targeting tumor antigens towards DCs. CONCLUSIONS: This new cancer immunotherapy has the potential to be cost-effective and broadly applicable to tumors that overexpress mesothelin. BioMed Central 2014-02-24 /pmc/articles/PMC3943805/ /pubmed/24565018 http://dx.doi.org/10.1186/1756-8722-7-15 Text en Copyright © 2014 Yuan et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Yuan, Jianping Kashiwagi, Satoshi Reeves, Patrick Nezivar, Jean Yang, Yuan Arrifin, Nadiah Hashim Nguyen, Mai Jean-Mary, Gilberte Tong, Xiaoyun Uppal, Paramjit Korochkina, Svetlana Forbes, Ben Chen, Tao Righi, Elda Bronson, Roderick Chen, Huabiao Orsulic, Sandra Brauns, Timothy Leblanc, Pierre Scholler, Nathalie Dranoff, Glenn Gelfand, Jeffrey Poznansky, Mark C A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma |
title | A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma |
title_full | A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma |
title_fullStr | A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma |
title_full_unstemmed | A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma |
title_short | A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma |
title_sort | novel mycobacterial hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943805/ https://www.ncbi.nlm.nih.gov/pubmed/24565018 http://dx.doi.org/10.1186/1756-8722-7-15 |
work_keys_str_mv | AT yuanjianping anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT kashiwagisatoshi anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT reevespatrick anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT nezivarjean anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT yangyuan anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT arrifinnadiahhashim anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT nguyenmai anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT jeanmarygilberte anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT tongxiaoyun anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT uppalparamjit anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT korochkinasvetlana anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT forbesben anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT chentao anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT righielda anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT bronsonroderick anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT chenhuabiao anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT orsulicsandra anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT braunstimothy anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT leblancpierre anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT schollernathalie anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT dranoffglenn anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT gelfandjeffrey anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT poznanskymarkc anovelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT yuanjianping novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT kashiwagisatoshi novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT reevespatrick novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT nezivarjean novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT yangyuan novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT arrifinnadiahhashim novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT nguyenmai novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT jeanmarygilberte novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT tongxiaoyun novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT uppalparamjit novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT korochkinasvetlana novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT forbesben novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT chentao novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT righielda novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT bronsonroderick novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT chenhuabiao novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT orsulicsandra novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT braunstimothy novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT leblancpierre novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT schollernathalie novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT dranoffglenn novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT gelfandjeffrey novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma AT poznanskymarkc novelmycobacterialhsp70containingfusionproteintargetingmesothelinaugmentsantitumorimmunityandprolongssurvivalinmurinemodelsofovariancancerandmesothelioma |